Shares of NeoGenomics (NASDAQ: NEO) surged 5.06% in pre-market trading on Tuesday, following the company's fourth-quarter earnings release that topped profit estimates but fell short on revenue.
NeoGenomics reported quarterly earnings of $0.04 per share for Q4 2024, beating the consensus analyst estimate of $0.03 per share by 33.3%. However, quarterly sales of $172 million missed analysts' expectations of $173.18 million by 0.68%. The revenue figure still represented a 10.6% increase from the same period a year ago.
While the mixed results garnered a positive initial reaction from investors, analysts cautioned that the revenue miss could temper enthusiasm going forward. "The earnings beat is encouraging, but NeoGenomics will need to demonstrate stronger sales growth to sustain momentum in the stock," said one Wall Street analyst. "Overall, the Q4 numbers give reasons for both optimism and caution on the company's prospects."
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。